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Abstract
Relationships between Oral MUC1 Expression 
and Salivary Hormones in Burning Mouth 
Syndrome
Kang, Jeong-Hyun, D.D.S., M.S.D.
Program in Oral Medicine and Oral Diagnosis
Department of Dental Science
Graduate School, Seoul National University
(Directed by Professor Hong-Seop Kho, D.D.S., M.S.D., Ph.D.)
Objectives: Burning mouth syndrome (BMS) is a complex disease whose 
etiopathophysiology is still vague, but dysregulated psychoendocrinological 
mechanisms and altered oral mucosal integrity have been regarded as significant 
factors. The aim of this study was to investigate the relationships among oral 
mucosal epithelial MUC1 expression, salivary female gonadal hormones, stress 
markers, and oral symptoms in BMS patients.
Materials and Methods: Thirty post-menopausal female patients with BMS (60.0 
± 5.0 years) were included. Clinical and psychological evaluations were performed 
and the expression level of oral mucosal epithelial MUC1 was analyzed. The levels
of cortisol, dehydroepiandrosterone (DHEA), 17β-estradiol, progesterone, 
chromogranin A, and blood contamination were determined from unstimulated 
whole saliva (UWS) and stimulated whole saliva (SWS) samples.
Results: Salivary progesterone level had significant positive correlations with oral 
mucosal epithelial MUC1 expression level and with salivary cortisol and DHEA
levels. The salivary level of 17β-estradiol showed significant positive correlations
with period of symptom duration, severity of effects of oral complaints on daily life, 
and results from psychological evaluations. Cortisol level in UWS and 
cortisol/DHEA ratio in UWS and SWS had negative correlations with severity of 
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oral burning sensation significantly. The severity of taste disturbance had positive 
correlations with results from psychometry significantly.
Conclusions: Dysregulated psychoendocrinological interactions might affect oral 
mucosal MUC1 expression and severity of oral burning sensation in post-
menopausal BMS patients.
___________________________________________________________________
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Burning mouth syndrome (BMS), a chronic oral mucosal pain disorder, is 
characterized by discomforts in the form of burning and/or stinging sensations that 
affect the oral mucosa without objective signs to justify the symptoms (Lopez-
Jornet et al., 2010; Scala et al., 2003). BMS mainly occurs in peri- or post-
menopaual women, and its etiology is multifactorial. Many physical and 
psychological conditions such as parafunctional habits, local nerve trauma, salivary 
gland dysfunctions, hormonal changes after menopause, depression, and anxiety
have been reported as potential predisposing factors (Bergdahl & Bergdahl, 1999; 
Patton et al., 2007; Scala et al., 2003).
Recent evidence has indicated central and/or peripheral neuropathic 
changes as the most significant etiopathogenic mechanisms in BMS development 
(Mendak-Ziółko et al., 2012; Puhakka et al., 2016; Yilmaz et al., 2007). Repetitive 
local irritations to the oral mucosa, oral parafunctional habits, reduction of salivary 
output, and changes in salivary composition can lead to peripheral neuropathic 
changes in oral mucosal tissues (Gorsky et al., 1991; Grushka & Sessle, 1991; Ko 
et al., 2011; Paterson et al., 1995). Decreased oral mucosal integrity resulting from
repetitive local stimuli and decreased lubrication capacity in the oral cavity might 
underly the occurrence of oral burning pain. 
The epithelia of the oral mucosa is continuously exposed to local injuries. 
Salivary glycoproteins such as mucins are crucial molecules for protecting the oral 
mucosa from these irritations by forming a protective cover on the oral mucosal 
surfaces (Slomiany et al., 1996). Secretory salivary mucins such as MUC5B and 
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MUC7 protect the oral mucosa indirectly by interacting with oral microorganisms 
and concentrating antimicrobials in mucin network close to the oral mucosal
surfaces (Wickström et al., 2000). Oral epithelial surface-bound mucin molecules, 
MUC1, protect the oral mucosa more directly (Gendler, 2001). MUC1, 
ubiquitously present in the glandular and luminal lining surfaces (Gendler, 2001;
Hattrup & Gendler, 2008), possesses extended negatively-charged carbohydrate
chains that protect the oral mucosa by forming network structures with secretory 
mucins and other proteins (Gibbins et al., 2015; Kullaa et al., 2014; Pramanik et al., 
2010).
Decreased expression of oral mucosal epithelial MUC1 in older adults
compared to young ones have been reported (Chang et al., 2011). Interestingly,
however, oral mucosal epithelial MUC1 expression was higher in post-menopausal 
BMS patients than age- and sex-matched controls (Kho et al., 2013). The 
adaptation of oral mucosal tissues to repetitive irritation has been suggested as a 
possible mechanism of the increase in oral MUC1 expression, but it remains to be 
answered whether psychoendocrinological dysregulations commonly found in 
BMS patients could affect oral MUC1 expression. Female gonadal hormones and 
stress-related biomarkers are known to be dysregulated in BMS patients (Kim et al., 
2012; Woda et al., 2009). Although the results have not been consistent, altered
levels of female gonadal hormones such as 17ß-estradiol, progesterone, and 
follicle-stimulating hormone (FSH) in serum and saliva have been found in patients
with BMS (Dias Fernandes et al., 2009; Gao et al., 2009; Kim et al., 2012). Altered 
levels of cortisol and dehydroepiandrosterone (DHEA), which reflect stressful
and/or adverse life events, have also been reported (Amenabar et al., 2008; Dias 
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Fernandes et al., 2009; Kim et al., 2012).
The relationships between oral MUC1 expression and salivary gonadal 
and stress hormones in healthy young female adults throughout the menstrual cycle
were investigated (Lee et al., 2015) and significant negative correlation between 
oral mucosal epithelial MUC1 expression and cortisol/DHEA ratio were found. A
significant negative correlation was also found between oral MUC1 expression and 
progesterone, especially during the mid-luteal phase, demonstrating that changes in
gonadal and stress hormones affect the oral mucosal defense. The present study 
was to extend previous findings about psychoendocrinological influences on oral 
mucosal defense to patients with BMS. The hypothesis was that dysregulated 
gonadal and stress hormones related to the development of BMS affect the 
increased oral mucosal epithelial MUC1 expression previously reported in patients
with BMS.
II. Literature review
1. Burning mouth syndrome (BMS)
BMS is a condition featured by subjective feeling described by the patient 
as pain and/or discomforts such as burning and stinging which occurred in the oral 
cavity, without clinical or laboratory evidences to justify these symptoms (Lopez-
Jornet et al., 2010; Scala et al., 2003). Classification of BMS are based on the 
clinical findings that ‘primary BMS’, in which the causes could not be clarified, 
and ‘secondary BMS’, attributed from local or systemic factors (Scala et al., 2003).
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Various factors could be involved in etiopathogenesis of burning 
sensations in the oral cavity, and these factors have been divided into local, 
systemic, and psychological categories. Repetitive local irritations to the oral 
mucosa could cause peripheral neuropathic changes in oral mucosal tissues 
(Gorsky et al., 1991; Grushka & Sessle, 1991; Ko et al., 2011; Paterson et al., 
1995). 
The relationships between BMS and systemic factors such as nutritional 
deficiencies and hormonal changes have been referred in previous reports 
(Femiano et al., 2008; Hugoson & Thorstensson, 1991; Lamey & Lamb, 1988; 
Moore et al., 2007). Decreased level of vitamin B12, ferritin, and folate had been 
found in BMS patients, and after prescribing supplement of vitamin B and ferrous 
sulphate, the symptoms alleviated (Hugoson & Thorstensson, 1991; Lamey & 
Lamb, 1988). Hormonal changes may have roles in occurrence of burning pain in 
the oral cavity. One study revealed that hypothyroidism could be suspicious cause 
of oral burning and dysguesia (Feminio et al., 2008). Another study focused on the 
role of diabetes mellitus in peripheral neuropathy in patients with type 1 diabetes 
and burning sensation and the results suggested that a neuropathic process may be 
an underlying source of BMS (Moore et al., 2007). 
It is well established that BMS patients showed higher levels of 
somatization, anxiety, or depression compared to controls (de Souza et al., 2011; 
Eli et al., 1994; Schiavone et al., 2012). However, the relationships between the 
extents of pain suffering and the results from psychometry have not shown 
consistency (Schiavone et al., 2012). One previous study mentioned that the 
psychometry data correlated with only the degree of affective pain, not that of 
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sensory pain in BMS patients (Carlson et al., 2000). These studies imply that 
psychopathologic factors may have an important role in BMS and support the 
multifactorial etiology, by interacting with physical changes. 
The primary location of the symptom is the tongue, and pain from BMS is 
characterized by continuous and spontaneous intense burning sensation in the oral 
cavity (Lopez-Jornet et al., 2010; Patton et al., 2007). Two specific clinical features 
such as dysguesia and xerostomia, usually occurs accordance with burning 
symptoms and these three symptoms are described as “symptomatic triad” (Scala et 
al., 2003). 
Many investigations have focused on the alteration in taste perception 
which might be related with burning pain. About 70% BMS patients were suffered 
from persistent taste disturbance (Femiano et al., 2008; Imura et al., 2016), and the 
altered taste was usually bitter and/or metallic (Ship et al., 1995). Both disturbance 
in the taste perception and burning pain might be a result of dysregulated sensory 
modalities at the level of small-diameter afferent fibers (Ship et al., 1995). 
Because no valid and standardized criteria used to diagnose BMS has 
been established yet, the true prevalence is uncertain. From National Health 
Interview survey in 1989, prevalence of burning sensation in the oral cavity in the 
US civilians age 18 and over was identified as 0.7% of all adults (Lipton et al., 
1993). The condition predominantly affects women, with a relation of 
approximately 3:1 compared to men. BMS is observed principally in middle-aged 
patients, particularly in postmenopausal women (Bergdahl & Bergdahl, 1999; 
Lamey & Lamb, 1988). Occurrence under 30 years is rare and never having been 
found in children or adolescent (van der Waal, 1990). These differences seem 
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mainly due to the biological, psychological, and sociocultural differences, but the 
pathophysiology of BMS is still controversial.
Because the pathophysiology of burning symptom is controversial, 
multidisciplinary approach is recommended for searching for management methods. 
If the burning pain is attributed from certain causes, such as Candidal infection, 
vitamin deficiency, anemia and so on, the first approach should try to alleviate 
these suspicious factors. However these kinds of treatments are usually not 
satisfactory. Then other medications such as anti-depressant, topical capsaicin, 
alpha-lipoic acid and so on could be considered. The most-used medication for 
treatment of BMS is clonazepam. The efficacy of topical (Gremeau-Richard et al., 
2004; Woda et al., 1998) and systemic clonazepam (Grushka et al., 1998) has been 
mentioned previously. Gabapentin, another anti-psychotic drug and alpha lipoic 
acid, a powerful neuroprotector seemed to have little effects in some patients with 
BMS but not in others (López-D'alessandro & Escovich, 2011). The tricyclc 
antidepressants such as nortriptyline and amitriptyline, serotonin inhibitors, and 
sertraline also have reported that these medication have effects in alleviating 
symptoms in the BMS patients (Lopez-Jornet et al., 2010).
The etiology of BMS is multifactorial and has not been fully understood 
yet. To approach the development of standardized diagnostic protocol and 
strategies for management, interdisciplinary research should be required. 
2. Menopause and gonadal hormonal changes
2.1. Menopause
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As life expectancy increase, a number of women who experienced
menopause have been increased. The World Health Organization has defined the 
menopause as the complete cessation of menstruation attributed to loss of ovarian 
follicular activity (World Health Organization, 1996). Other terms, such as 
perimenopause, which refers to time starting a few years prior and sustained after 
the occurrence of menopause, and climacteric, that means time after the 
termination of reproductive function are used. 
The median age of beginning menopause has been mentioned as 45.7 years 
(McKinlay et al., 1992) in women in United States, and as 48 years in Korean 
women (Hong et al., 2006). The primary determinant factor of age of menopause is 
genetics, but it is thought that general health status also could affect the timing of 
menopause. Smoking seemed to be related with onset of menopause 1 to 2 years 
earlier (McKinlay et al., 1992). Greater body mass has been thought to be related
with delayed menopause (McKinlay et al., 1992), and malnourishment and 
vegetarianism have been thought to be associated with earlier onset of menopause 
(Biela, 2002). Furthermore women with shorter menstrual cycle showed earlier 
menopause, and multigravida women or those who used oral contraceptives 
showed later menopause (Harlow & Signorello, 2000). 
The menopausal transition is accompanied with many biological, physical 
and neuroendocrinological changes. Many symptoms and signs are related to 
female gonadal hormonal deficiency, and merge with issues of natural aging. For 
example, the risk of cardiovascular diseases during postmenopausal period 
increases and the rate of bone loss is accelerated (Chahal & Drake, 2007; Riggs &
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Melton, 1986). Moreover hot flush and cognitive disturbance could occur (Hammar 
et al., 1998; Shaywitz et al., 1999). Hormone replacement therapies were 
developed to reduce these symptoms, and some of them were effective (American 
College of Physicians, 1992). 
As the aging population and life expectancy increases, medical care 
targeted to postmenopausal women becomes an important issues of future medicine 
and dentistry. Further research and clinical consideration about this would be 
needed for researchers and clinicians. 
2.2. Female gonadal hormonal changes
2.2.1. Estradiol
The Stages of Reproductive Aging Workshop demonstrated simplified 
reproductive aging stages in 2012 (The Stages of Reproductive Aging Workshop 
+10, STRAW + 10) (Harlow et al., 2012). According to this system, during early 
(stage -2) and late (stage -1) menopausal transition stages, shortened menstrual 
cycle length and elevated concentrations of follicular stimulating hormone (FSH) 
and low Anti-Mullerian hormone (AMH) are detected, and functional capacity of 
the ovary is also decreased (Harlow et al., 2012). The elevation in FSH 
concentrations could be detected several years before menopause and continues 
increasing 2 years after menopause (stage +1). On the other hand, estradiol levels 
decrease during stage -2 to stage +1 and are stabilized about 2 years after 
menopause because functional capacity of the ovary is decreased as aging process 
of reproductive system of women proceeds (Randolf et al., 2011). Elevated 
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gonadotropin levels are sustained due to reduced secretion of estratiol (Randolf et 
al., 2011).
The most remarked hormonal changes during perimenopause are 
significant reduction in estradiol (Yen, 1977). The estrone, a conjugate form of
estrogen which acts as circulating reservoir of estradiol is less reduced than 
estradiol because estrone is produced mainly by peripheral aromatization from 
androgen, not only by ovary (Yen, 1977).
Abundant human research has suggested that ovarian failure induce the 
menopause. Eventually follicular activity ceases, estrogen concentration fall and 
other gonadotropins rise accordance with decreased estrogen levels. Thus the 
changes of levels of estradiol would have key role to understand hormonal changes 
during menopause.
2.2.2. Progesterone
In perimenopausal women, the ovary shows reduced number of follicles, 
and the hormonal changes of older women are related with the depletion of ovarian 
follicles. In the early perimenopausal stage, the concentration of estradiol was 
reduced, but normal luteal phase concentration of progesterone was observed 
(Sherman et al., 1976). In later stages, diminished secretions of both estradiol and 
progesterone were detected (Sherman et al., 1976). 
Anovulation increases as women progress through the transition to 
menopause. Several studies focused on the relationships between longer 
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anovulation, declining luteal secretion, and decreased levels of pregnanolone, the 
inactive metabolite of progesterone (O’Connor et al., 2009; te Velde & Pearson, 
2002). Thus gamatogenic ovarian failure may lead to decreased secretion of 
progesterone and decreased levels of progesterone or its metabolite may have a role 
in increased anovulation and declining luteal secretion.
3. Stress markers
3.1. Cortisol
Cortisol is one of the main stress hormones which mediate stress and 
physiological body responses. Cortisol is synthesized by cholesterol in the zona 
fasciculata of human adrenal gland cortex. The secretion and biological response of 
cortisol is regulated by hypothalamic-pituitary-adrenal (HPA) axis. Under stress, 
the medial parvocellar region in the hypothalamus release corticotropin-releasing 
hormone (CRH), and CRH binds to receptors in the anterior pituitary to promote
the production of adrenocorticotropic hormone (ACTH) (Herman & Cullinan, 
1997). Circulating ACTH is main regulator of glucocorticoid, mainly cortisol in the 
adrenal gland cortex. Secretory cortisol finally maintains whole body homeostasis
and the organisms’ response to stress. The negative feedback of HPA axis on the 
ACTH secretory response confines the duration of the tissue exposure to cortisol, 
and minimize the catabolic, anti-reproductive, and immunosuppressive effects of 
cortisol (Tsigos & Chrousos, 2002). 
Under acute stress, an increased level of cortisol induces catabolic 
processes to provide more energy to the tissue, and increased cortisol levels return 
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to the basal levels by negative feedback of HPA axis. On the contrary, under 
chronic stress, results are heterogeneous with studies, reporting blunted as well as 
heightened cortisol levels or no differences in the HPA axis response (Kudielka et 
al., 2009; Lightman. 2008). It is generally accepted that exposure to stress can 
cause heightened cortisol levels. If higher cortisol level is prolonged for a while, 
elevated levels of cortisol could damage on hippocampal and cortical neurons and 
finally dysregulate the HPA axis mechanisms (Sapolsky et al., 1986). Thus when 
researching the mechanisms of chronic pain, dysregulated HPA axis should be 
considered seriously. 
3.2. Dehydroepiandrosterone (DHEA)
DHEA and its sulphate form (DHEA-S) are sex steroid precursors, and 
secreted by the zona fasciculate layer of adrenal cortex. Though concentration of 
DHEA-S are much higher than concentration of DHEA due to increased half-life 
and decreased clearance rate of DHEA-S than that of DHEA, only desulphated
form of DHEA is biologically active and DHEA-S is regarded as reservior of 
DHEA.
The secretion rates of DHEA and DHEA-S are controlled by CRH and 
ACTH. The changes of levels of DHEA under acute or chronic stress have been
reported several times in previous studies. The elevated concentration of DHEA 
under acute physiologic and psychosocial stress has been reported (Lennartsson et 
al., 2012; Oberbeck et al., 1998). On the contrary, chronic stress seems to be 
associated with unchanged or decreased DHEA concentrations (Oberbeck et al., 
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1998). Interestingly, dissociation of adrenal DHEA and cortisol release during 
chronic stress is observed (Parker et al., 1985) and this may imply that DHEA 
secretion is controlled independently from cortisol. 
Previous studies demonstrated that DHEA levels declined about 30-50% in 
age 50s compared to those of in 30s. This might be due to the decreased mass of 
the zona reticularis (Kushnir et al., 2010; Parker et al., 1985). The hypothesis that 
the stress-induced DHEA increase is also decreased at older age could be deduced, 
and one study showed that administration of ACTH or CRH lead to elevate cortisol 
levels in same extents in both old and young subjects but the increase in DHEA and 
DHEA-S was much less in old subjects (Vermeulen et al., 1982). 
3.3. Cortisol/DHEA ratio
Despite the same site of origin and being induced by a similar set of 
hormones, cortisol and DHEA mediate opposing biological and neurologic 
functions. Because DHEA has anabolic and anti-glucocorticoid effects and shows 
adverse effects of cortisol, the ratio of cortisol and DHEA means the equilibrium
between catabolic and anabolic activities, and has been regarded as indicator of 
“functional cortisol effect”.
Under acute or chronic stress, cortisol/DHEA ratio shows different patterns. 
Under acute stress, DHEA elevation was paralleled by increased cortisol levels, but 
the peak of DHEA preceded that of cortisol (Izawa et al., 2008; Oberbeck et al., 
1998). On the contrary, if stress sustained for a while, cortisol level was decreased,
DHEA level showed blunted response, and cortisol/DHEA, an indicator of the 
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‘functional cortisol effect’, was decreased (Gallagher et al., 2016; Mouthaan et al., 
2014). Thus cortisol/DHEA could be a better marker of severity of symptoms than 
cortisol or DHEA level alone in patients under chronic stress. 
3.4. Chromogranin A (CgA)
CgA is an acidic glycoprotein which is secreted accordance with 
catecholamine from the adrenal medulla and the sympathetic nerve endings 
(Takiyyuddin et al., 1994). Numerous pairs of amino acids consist of CgA 
structures. After cleavage by the prohormone convertases of the neurosecretory 
granules, the proteolytic fragments of CgA such as catestatin, vasostatins, 
pancreastatin, and parastatin finally have broad range of regulatory activities on the 
cardiovascular, endocrine, and immune systems (Helle et al., 2007).
CgA has been regarded as valid indicator of sympathoadrenal activity. 
Moreover concentration of CgA in saliva was elevated under conditions of stress 
(Nakane et al., 2002). Salivary CgA has not been regarded as originating from 
blood but rather is released from the submandibular gland duct into saliva by 
autonomic stimulation (Saruta et al., 2005). The durability and small time lag 
regarded as advantages of salivary CgA as a biomarker of mental stress (Gallina et 
al., 2011), but the levels of CgA could be affected by symptoms of oral dryness or 
reduced salivary flow rate and showed circadian variations as those of cortisol 
(Den et al., 2007). Thus when using salivary CgA as a stress marker, the conditions 
in oral cavities of the subjects and sampling time should be considered.
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4. Oral mucosal defense and MUC1
Mucins are defined as glycoproteins containing 50-90% of their molecular 
sizes as oligosaccharides (Gendler, 2001). There are two types of mucins. Firstly, 
secreted mucins are the front line of protection for epithelial surface, acting as 
physical covers between extracellular environment and mucosal surface by gel-
forming. Secretory salivary mucins such as MUC5B and MUC7 protect the oral 
mucosa indirectly by interacting with oral microorganisms and concentrating 
antimicrobials in mucin network close to the oral mucosal surfaces (Wickström et 
al., 2000). Another type of mucins are tethered transmembrane mucins which are 
regarded as next line of defense. This type of mucins act like sensor of any 
disturbance to the cell surfaces and signals this information to the inside of the cell 
(Gendler, 2001). MUC1 is a second type of mucin which is a single pass 
transmembrane protein with a heavily glycosylated extracellular domain that 
extends up to 200-500 μm from the cell surface (Gendler, 2001; Hattrup & Gendler, 
2008). MUC 1 is routinely expressed in the glandular and luminal epithelial lining 
cells of the mammary gland, esophagus, stomach, duodenum, pancreas, uterus, 
prostate, lung, and oral cavity. (Gendler, 2001; Hattrup & Gendler, 2008). The 
extended negatively charged sugar chains of MUC1 make physical covers and 
provide an anti-adhesive property to MUC1 so confining accessibility from 
pathogen and preventing pathogenic colonization, resulting in lubricating and 
protecting the underlying epithelia from both physical and chemical irritations 
(Kufe, 2009; Schroten et al., 1992; Yolken et al., 1992). MUC1 in the oral cavity 
protect the oral mucosa more directly by forming network structures with secretory 
mucins and other proteins (Gibbins et al., 2015; Kullaa et al., 2014; Pramanik et al., 
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2010).
Several factors have been suggested as having a role in controlling the 
amount of epithelial MUC1 expression in the oral cavity. Higher amount of oral 
MUC1 expression was detected in adolescent with higher frequency of dental 
caries (Gabryel-Porowska et al., 2014). Moreover BMS patients showed higher 
oral mucosal epithelial MUC1 expression than age- and sex-matched controls (Kho 
et al., 2013), and healthy young women showed different patterns of oral MUC1 
expressions throughout their menstrual cycles and stages (Lee et al., 2015). Thus it 
seems that the adaptation mechanisms of oral mucosal tissues from local irritation 
and endocrinological regulations have roles in controlling the amount of oral 
MUC1 expressions, but still the specific mechanisms remain controversial. 
5. Saliva as a diagnostic fluid 
Saliva is a complex mixture composed of secretions from major and 
minor salivary glands and several other constituents, such as gingival crevicular 
fluid, microorganisms, desquamated epithelial cells, and food debris. Saliva has 
been considered as ‘a mirror of body’ because variety of analytes from systemic 
sources could reach to the oral cavity through various pathways. Even though 
blood and urine have been used as the most widely used laboratory setting 
diagnostic fluid, whole saliva has been considered as an alternative of blood and 
urine because of its non-invasive and relatively simple collecting procedures
(Malamud, 1993). Saliva contains various biomarkers which make it possible for 
bioassays developed as point-of-care device such as detection of human 
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immunodeficiency virus, human papillomavirus, hepatitis C virus antibodies, and 
RNA from Zika virus (Corstjens et al., 2016; Priye et al., 2017). Furthermore many 
commercial kits for monitoring hormones and lipid soluble drugs are also available 
and have been applied in everyday clinics (Chiappin et al., 2007; Saxena and 
Kumar, 2015; Wood, 2009). The rapid detections of other life-threatening diseases 
such as cancers, kidney diseases, Alzheimer’s disease, Parkinson’s diseases, and 
oral cancer by saliva have been also applied (Master et al., 2015; Peng et al., 2013; 
Shi et al., 2011; Xiao et al., 2015). 
Saliva has several advantages and disadvantages compared to urine and 
blood such as easy and non-invasive collecting procedures. However saliva has 
disadvantages such as wide normal range of analytes, low analytes concentration 
and lack of standardized procedures. Levels of analytes in plasma such as steroid 
hormones usually show up to 10 folds higher concentration than those in saliva 
(Chiappin et al., 2007; Nune et al., 2015). Because of higher levels of analytes in 
serum compared to those in saliva, if blood leakage reaches a certain threshold, the 
salivary levels of analytes should be artificially elevated (Kivlighan et al., 2004; 
Schwartz and Granger, 2004). 
Early studies of salivary diagnosis focused the biomarkers of specific 
disease in saliva without understating of origin of these biomarkers. However 
nowadays advances in oral fluid biomarkers have been extremely developed by 
molecular biological knowledge and advanced experimental technologies. The 
future research about this field would try to improve diagnostic efficacy of saliva 
and widen the spectrum of diagnosis to other systemic diseases in a point of care.  
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III. Materials and methods 
1. Participants  
Thirty-seven post-menopausal women were recruited from patients who 
attended the Department of Oral Medicine (Seoul National University Dental 
Hospital, Seoul, South Korea) with complaints of a burning sensation and 
dysesthesia in the oral cavity without objective clinical abnormality between 1 
Nov., 2014 and 30 Sep., 2015. Exclusion criteria for the participants were; smoker, 
having uncontrolled diabetes, having a history of malignant cancer, having a 
history of beam radiation and/or radioisotope treatment in the head and neck region, 
a medication history of immunosuppressants and/or cytotoxic drugs, and being 
incapable of communication. 
Of thirty-seven participants, two patients were excluded due to high levels
of blood contamination in their saliva samples. Because hormone levels in the 
blood are much higher than those in the saliva, the high amount of blood in saliva 
samples lead to incorrect results. The cut-off values were 2.0 mg/dL of transferrin 
in the case of unstimulated whole saliva (UWS) and 1.0 mg/dL of transferrin in 
stimulated whole saliva (SWS) (Schwartz & Granger, 2004). One patient was 
excluded because she became menopause one year before participation. It has been 
reported that gonadal hormonal levels reach stabilization about at least two years 
after menopause (Harlow et al., 2012). One patient was excluded because of low 
serum vitamin B12 level and high serum fasting glucose level, and another due to
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decreased serum ferritin and hemoglobin levels. One patient withdrew without 
specific reason, leaving a final total of thirty patients (mean age, 60.0 ± 5.0 years) 
in the study. The research protocol was reviewed in compliance with the Helsinki 
Declaration and approved by the Institutional Review Board of the Seoul National 
University Dental Hospital (#CRI14036) in 10 Oct., 2014 and informed consents 
were obtained from all participants. 
2. Clinical evaluation 
Clinical evaluation procedures for the participants included oral 
examination, panoramic radiography, psychological evaluation [Symptom 
Checklist-90-Revised (SCL-90-R)] (Derogatis & Cleary, 1977), and salivary flow 
rate measurement. A questionnaire was used to evaluate subjective discomforts, 
and consisted of questions about duration and areas of symptoms, characteristics of 
discomfort (burning, aching, stinging, itching, numbness, taste disturbance, dry 
mouth, and sore throat), and the effect of oral complaints on daily life (Eff-life). 
The severities of oral discomforts and Eff-life were scored by a visual-analog-scale 
(VAS) (0-10 cm, with 10 cm indicating the worst imaginable discomfort). Oral 
parafunctional habits, including pressing the tongue against the teeth, tongue or 
cheek biting, diurnal tooth clenching, and nocturnal clenching or bruxing were also 
recorded.  
3. Psychological evaluation 
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The SCL-90-R was used to examine the psychological status of the 
participants. The SCL-90-R is a tool for evaluating psychological symptoms by 
analyzing the answers to 90 questions, and provides results of the nine symptom 
dimensions, such as somatization (SOM), obsessive-compulsive (O-C), 
interpersonal sensitivity (I-S), depression (DEP), anxiety (ANX), hostility (HOS), 
phobic anxiety (PHOB), paranoid ideation (PAR), and psychoticism (PSY). Three 
global functioning indices, such as global severity index (GSI), positive symptom 
distress index (PSDI), and positive symptom total (PST) were also provided. 
4. Blood tests 
Blood tests were performed to rule out other possible systemic factors that 
may cause oral burning pain and/or abnormal oral sensations. The tests included 
complete blood counts with leukocyte differential and hematinic-related 
components such as iron, ferritin, vitamin B12, and folate. Blood glucose, liver 
function tests (total protein, albumin, total bilirubin, aspartate aminotransferase, 
alanine aminotransferase, alkaline phosphatase, and cholesterol), kidney function 
tests (blood urea nitrogen and creatinine), and thyroid function tests [T3
(triiodothyronine), free T4 (thyroxine), and TSH (thyroid-stimulating hormone)] 
were also performed. In addition, calcium, phosphorus, magnesium, and zinc levels 
were analyzed.
5. Collection of saliva samples  
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Saliva was collected between 9:00 a.m. and 11:00 a.m. to minimize 
variability due to circadian rhythm. The participants reported wake-up times from 
5:30 a.m. to 7:30 a.m., and the mean time interval between waking-up and saliva 
collection was 3.3 ± 1.1 hours. Eating and drinking were prohibited for 2 hours 
prior to the saliva sampling. UWS was collected for 15 min by drooling the saliva 
into a tube. Mechanical stimulation, chewing of 1 g of gum base, was used to 
stimulate salivary flow. The saliva collected for the first 2 min was discarded, and 
then SWS was collected for the next 10 min with the mechanical chewing 
stimulation. Salivary flow rate was expressed as mL/min.
Two milliliters of SWS from each participant were added to RNA 
stabilizing solution (Oragene RNA RE-100, DNA Genotek Inc., Ottawa, ON, 
Canada) and used for RNA extraction. The UWS and remnant SWS samples were 
centrifuged at 10,000 xg for 20 min at 4°C to remove any cellular debris. The 
clarified supernatants were aliquoted and frozen at -70°C for analytic experiments.
6. Determination of oral mucosal epithelial MUC1 expression
level
Total RNA was extracted from the mixture of Oragene RNA RE-100
(DNA Genotek Inc.) and SWS sample using a RNeasy Mini kit (Qiagen, Hilden, 
Germany). The concentration of RNA in each sample was determined at 260 nm 
using a spectrophotometer (Nanodrop 1000, Thermo Fisher Scientific, Wilmington, 
DE, USA). The mean amount of total RNA was 24.2 ± 14.6 μg. The absorbance 
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ratio at A260/280 of each sample was 1.8 - 2.0, and the extracted RNA samples 
were stored at -70°C.  
The real-time PCR experiments were performed to quantify MUC1 
mRNA levels relative to ß-actin and GAPDH mRNA levels, as described in 
previous reports (Kho et al., 2013; Lee et al., 2015). Briefly, quantitative PCR 
reactions were performed with an ABI 7500 (Applied Biosystems, Foster City, CA, 
USA) using TaqMan probes (Applied Biosystems) and cDNA synthesized using 1 
μg of total RNA. The crossing points of MUC1 with both ß-actin and GAPDH 
were applied to the formula, 2-(MUC1-ß-actin(or GAPDH)), to calculate the relative level of 
MUC1 to both housekeeping genes. Finally, the averaged fold ratios from both 
housekeeping genes were used as the relative MUC1 mRNA level. Each 
experiment was performed in duplicate. Two reactions, one without template and 
one without reverse transcriptase, were also performed as negative controls.
7. Determination of cortisol, DHEA, 17ß-estradiol, 
progesterone, chromogranin A, and blood contamination in 
saliva samples  
The concentrations of cortisol, DHEA, 17ß-estradiol, and progesterone 
were analyzed from UWS and SWS by enzyme immunoassays (Salimetrics, State 
College, PA, USA). Cortisol/DHEA ratio was obtained by dividing the 
concentraion of cortisol by that of DHEA in the same unit. Chromogranin A (CgA)
level was also determined using an immunoassay (Yanaihara institute Inc., 
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Shizuoka, Japan). To determine the level of blood contamination in saliva samples, 
an immunoassay measuring the concentration of transferrin in saliva was used
(Salimetrics, State College, PA, USA). All assays were duplicated and data were 
averaged. In the UWS of one participant, analyses of 2 items, DHEA and CgA,
could not be performed due to a shortage of sample. 
Intra-assay and inter-assay coefficients of variation for the cortisol assay 
were 3.0% and 3.0%, respectively, and its sensitivity was 0.007 μg/dL. Those for 
DHEA were 5.6% and 8.2%, and its sensitivity was 5.0 pg/mL, those for 17ß-
estradiol were 8.1% and 8.9%, and its sensitivity was 0.1 pg/mL, those for 
progesterone were 6.2% and 7.6%, and its sensitivity was 5.0 pg/mL, those for 
CgA were 10.5% and 13.3%, and its sensitivity was 0.14 pmol/mL, those for blood 
contamination were 4.9% and 7.1%, and its sensitivity was 0.08 mg/dL. The cross-
reactivity of the cortisol assay with cortisone was 0.13%. 
8. Statistics 
Based on the Kolmogorov-Smirnov normality test, data in this study were 
normally distributed; therefore, parametric tests were applied. The paired T-test and 
Pearson’s correlation analysis were used. All tests were two-sided and P-values less 
than 0.05 were considered statistically significant.  
IV. Results  
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1. BMS questionnaires 
Most patients (n = 28, 93.3%) complained of oral burning symptoms. Two 
patients who did not complain of burning pain reported an itching sensation and an 
aching type of pain, respectively. Aching sensation was the second most common 
type of pain and was reported by 18 patients (60.0%). Twenty patients (66.7%) 
complained of oral dryness and 18 (60.0%) complained of taste disturbance. The 
mean duration of discomforts was 28.1 ± 39.3 months. The severity (VAS score) of 
burning sensation was 6.1 ± 2.9 and that of Eff-life was 4.4 ± 3.0. All patients 
reported the tongue as the main symptom area, especially the tongue tip (n = 23, 
76.7%). Other than the tongue, pain was reported in the lip by nine patients, the 
palate by seven patients, and the gingiva by five patients. Pressing the tongue 
against the teeth was the most common habit reported by the patients (n = 8, 26.7%) 
(Table 1). 
2. Salivary flow rate and SCL-90-R
The mean flow rate of whole saliva in the unstimulated state was 0.27 ± 
0.17 mL/min and that in the stimulated condition by gum chewing was 1.11 ± 0.48 
mL/min (Table 1). According to the SCL-90-R results, the T-scores of all nine 
symptom dimensions were in the range of 30 - 60 in all patients except two. In one 
patient, the T-score was higher than 60 in SOM and in another patient, T-score were 
higher than 60 in SOM, O-C, DEP, and ANX (data not shown). 
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3. Salivary hormone and blood contamination levels 
The mean concentrations of almost every salivary analyte in UWS tended 
to be higher than those in SWS, but only mean levels of progesterone, CgA, and 
blood contamination were significantly different between UWS and SWS (Table 2).  
4. Correlations among levels of salivary analytes and 
severities of oral symptoms
The level of 17β-estradiol in UWS had a significant positive correlation 
with period of symptom duration (r = 0.626, P < 0.001) and that in SWS showed a 
significant positive correlation with VAS score of Eff-life (r = 0.397, P = 0.030). 
The cortisol level in UWS had a significant negative correlation with severity of 
burning sensation (r = -0.391, P = 0.032), but the DHEA levels in both UWS and 
SWS did not show any statistical significances with severity of burning sensation. 
Cortisol/DHEA in both UWS (r = -0.517, P = 0.004) and SWS (r = -0.401, P = 
0.028) had also significant negative correlations with severity of burning pain 
(Table 3).  
5. Correlations among levels of salivary analytes and oral 
mucosal MUC1 expression 
Correlations between all variables were analyzed in both UWS and SWS. 
The most prominent finding was that the levels of progesterone in UWS (r = 0.550, 
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P = 0.002) and SWS (r = 0.414, P = 0.023) showed significant positive correlations 
with the level of oral mucosal MUC1 expression. Progesterone levels also had 
positive correlations with cortisol and DHEA levels significantly, with higher level 
of significance between progesterone and DHEA than between progesterone and 
cortisol. Cortisol/DHEA showed significant negative correlations with DHEA 
levels in both UWS (r = -0.633, P < 0.001) and SWS (r = -0.626, P < 0.001), but 
not significant positive correlations with cortisol levels. In addition, the levels of 
17β-estradiol showed significant positive correlations with the level of 
progesterone in UWS (r = 0.418, P = 0.022) and with the level of DHEA in SWS (r 
= 0.363, P = 0.049) (Tables 4 and 5). 
Concentrations of all analytes except CgA were not affected by the blood 
contamination levels in either UWS or SWS. The levels of CgA had significant 
positive correlations with the levels of blood contamination both in UWS (r = 
0.571, P = 0.001) and SWS (r = 0.440, P = 0.015). Salivary flow rates did not 
affect the levels of salivary analytes, except for the level of CgA in SWS (r = -
0.439, P = 0.015) (Tables 4 and 5).  
6. Correlations among symptoms, levels of salivary analytes,
and SCL-90-R results
The severity of burning pain did not correlate with the results of the 
psychometry, but the VAS scores of aching sensation (r = 0.380, P = 0.038) and 
Eff-life (r = 0.377, P = 0.040) had positive correlations with the score of HOS 
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significantly. The duration of symptoms also had a positive correlation with the 
score of O-C (r = 0.363, P = 0.049). Interestingly, there were significant positive 
relationships between the severity of taste disturbance and the results of 
psychometry, for DEP (r = 0.492, P = 0.006), ANX (r = 0.418, P = 0.022), PHOB 
(r = 0.407, P = 0.026), PSY (r = 0.383, P = 0.037), and GSI (r = 0.412, P = 0.024). 
The severity of numbness followed, with significant positive correlations with the 
scores of PHOB (r = 0.751, P < 0.001), GSI (r = 0.361, P = 0.049), and PST (r = 
0.443, P = 0.014) (Supplementary Table S1).
17β-Estradiol was the only salivary gonadal hormone that had significant 
correlations with the results of the psychometry. The levels of 17β-estradiol in both 
UWS (r = 0.412, P = 0.024) and SWS (r = 0.503, P = 0.005) showed positive 
correlations with the score of O-C significantly. The level of 17β-estradiol in SWS 
also had positive correlations with the scores of DEP (r = 0.420, P = 0.021), PSY (r 
= 0.461, P = 0.010), GSI (r = 0.397, P = 0.030), and PST (r = 0.399, P = 0.029). 
The level of CgA in SWS showed negative correlations with the scores of I-S (r = -
0.386, P = 0.035), HOS (r = -0.475, P = 0.008), and PAR (r = -0.367, P = 0.046) 
(Supplementary Table S2).
V. Discussion
Several studies have tried to explain the etiopathogenic mechanisms of 
BMS based on altered levels of gonadal and stress hormones and oral MUC1 
expression pattern. It has been reported that BMS patients had elevated levels of 
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FSH and cortisol and decreased level of estradiol in their blood samples (Amenabar 
et al., 2008; Gao et al., 2009). On the other hand, BMS patients had increased 17β-
estradiol and cortisol levels and decreased DHEA level in their saliva samples 
compared to age- and sex-matched controls (Dias Fernandes et al., 2009; Kim et al., 
2012). Given that patients with BMS with abnormal gonadal and stress hormone 
levels also had higher level of oral mucosal MUC1 expression compared to elderly
subjects without oral burning pain (Chang et al., 2011; Kho et al., 2013), the focus 
of this study was the influences of dysregulated gonadal and stress hormones on 
oral mucosal MUC1 in patients with BMS. 
The effects of gonadal hormones such as progesterone on uterine MUC1 
expression related with embryo implantation have been reported (Dharmaraj et al., 
2010; Meseguer et al., 2001). However, there has been only one previous report on 
the influence of gonadal and stress hormones on oral mucosal MUC1, featuring 
young healthy females throughout their menstruation cycles (Lee et al., 2015). That 
study found that the expression level of oral mucosal epithelial MUC1 was 
negatively correlated with salivary cortisol/DHEA throughout the whole menstrual 
cycle and was also negatively correlated with salivary cortisol, cortisol/DHEA, and 
progesterone, especially during the mid-luteal phase (Lee et al., 2015). These 
findings imply that stress-related endocrinological interactions decrease oral 
mucosal MUC1 expression in healthy young female adults. 
The novel findings of this study were that the level of salivary 
progesterone showed significant positive correlations with the levels of oral 
mucosal MUC1 expression and salivary cortisol in BMS patients, in contrast to 
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results from previous studies. A relationship between progesterone and cortisol has 
been previously reported (Liening et al., 2010; Reinfenstein, 1946; Wirth et al., 
2007). The concept that stress and increased activity of the hypothalamic-pituitary-
adrenal (HPA) axis have the potential to inhibit the hypothalamic-pituitary-gonadal 
(HPG) axis has been widely accepted (Reifenstein, 1946). In menopausal BMS 
patients with sustained oral pain under ceased reproductive function, the effects of 
stress on the adrenal glands would be much greater than those on the gonadal 
glands. The adrenal glands could secrete progesterone as an important intermediary 
precursor in synthesis of the adrenal corticoids (bartosuk et al., 1957), at a rate 
controlled by adrenocorticotropic hormone (ACTH) (Holzbauer & Newport, 1969). 
Thus, under conditions of stress, ACTH might up-regulate the secretion of 
progesterone as well as cortisol in the adrenal gland. In the same manner, a positive 
correlation between salivary levels of progesterone and cortisol has also been 
observed in men and women taking hormonal oral contraceptives (Liening et al., 
2010; Wirth et al., 2007). The mechanisms underlying the positive correlation 
between progesterone and oral mucosal MUC1 could not be fully explained. 
Increased oral mucosal MUC1 expression could be the result of adaptation in the
oral mucosal tissues to repetitive oral parafunction and chronic local irritation (Kho 
et al., 2013), which might be related to inability to cope with increased 
psychological stress. However, hormonal changes related to psychological stress 
might affect the level of oral mucosal MUC1 expression. Further research about 
psychoendocrinological influences on oral mucosal tissues at the molecular level is 
needed. 
The involvement of 17β-estradiol in the subjective pain perception 
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process could be inferred from its positive correlations with period of symptom
duration, severity of Eff-life, and results from the psychological evaluation in the 
present study. Though the exact role of estrogen in pain cognition is inconclusive, 
the results of many studies have indicated that female gonadal hormones are 
involved in pain modulation. The effects of endogenous hormones have been 
investigated by studies on gender differences in pain perception or menstrual-
related changes of pain (Ge et al., 2006; Mathew et al., 2013). The effects of 
exogenous hormones have been investigated by studies on changes of pain 
perception in post-menopausal women by hormone replacement therapy (Fillingim 
& Edwards, 2001). Both kinds of studies showed that increase or fluctuation of 
estrogen level is related to decrease of pain thresholds and increase of pain 
perception. Estrogen is also known to affect emotion. Estrogen replacement 
therapy has been suggested to improve psychological function and general well-
being in postmenopausal women (Ditkoff et al., 1991). However, a significant 
increase in negative mood and anxiety has been reported in postmenopausal 
women following estrogen administration (Newhouse et al., 2008), suggesting that 
the impact of estrogen on psychological status is not straightforward and may vary 
depending on the situation. Therefore, it could be suggested that the altered level of 
17β-estradiol in patients with BMS might be associated with the subjective 
awareness of oral discomforts and altered psychological status.
The negative correlations between cortisol or cortisol/DHEA and severity 
of burning sensation imply an effect of stress on the subjective awareness of 
discomforts in patients with BMS. In the acute stress phase, cortisol and DHEA 
levels are elevated, with the peak of DHEA preceding that of cortisol (Izawa et al., 
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2008; Vermes & Beishuizen, 2001). However, in subjects under sustained stress,
cortisol level was decreased, DHEA level showed blunted response, and 
cortisol/DHEA, an indicator of the ‘functional cortisol effect’, was decreased 
(Gallagher et al., 2016; Mouthaan et al., 2014). The results of this study indicate 
that psychoendocrinological interactions affect the severity of symptoms in patients 
with BMS, and that cortisol/DHEA could be a better marker of severity of 
symptoms than cortisol or DHEA level alone in patients with BMS. 
Neurological interactions between pain and taste perceptions are well 
known (Bartoshuk et al., 2005), and taste disturbance is a common symptom in 
patients with BMS (Femiano et al., 2008; Imura et al., 2016). The association of 
taste disturbance with psychological conditions, including stress, depression, and 
especially anxiety has been reported (Bergdahl & Bergdahl, 2002; Davies et al., 
2016), which supports the positive correlations between taste disturbance and 
psychometry in the present study. Taste thresholds and perceptions have been 
reported to be affected by the level of cortisol changed by circadian rhythms or 
acute stress in healthy subjects (Al’Absi et al., 2012; Fujimura et al., 1990). 
However, a relationship between salivary cortisol level and severity of taste 
disturbance was not found in the present study. Occurrence and severity of taste 
disturbance are thought to be affected by complex psychoneuroendocrinological 
interactions, not just cortisol level in post-menopausal BMS patients with a 
dysregulated HPA axis.
It is well known that psychologic indices such as somatization, anxiety, or 
depression tend to be higher in BMS patients (Eli et al., 1994; de Souza et al., 2011; 
31
Schiavone et al., 2012). However, the relationships between the degree of pain 
suffering and the results of psychometry are not always consistent, which may 
depend on the type of psychometry tools (Schiavone et al., 2012). It has also been 
reported that the psychometry data correlated with only the affective pain rating, 
not the sensory pain rating in BMS patients (Carlson et al., 2000). Above results 
showed no significant correlations between the severity of burning pain and the 
results of the psychometry. These results could be affected by the facts that the T-
scores of psychometry in the BMS patients included in this study were not very 
high and we evaluated the sensory pain rating.
There are limitations in the present study. First, because of lack of a 
control group, the results could not show the degree of abnormalities in stress and 
gonadal homonal levels and patterns of MUC1 expression in patients with BMS. 
However, based on the findings from previous reports, it could be hypothesized the 
existence of relationships between altered gonadal and/or stress hormonal levels 
and oral mucosal MUC1 expression patterns in patients with BMS. Thus, it is 
thought that the lack of a control group does not critically lessen the value of this 
study. Second, as relatively small numbers of subjects were included and the levels 
of correlation coefficients were relatively weak and moderate, the influences of 
confounding factors should be considered when interpreting the results.
In conclusion, the etiology of BMS is multifactorial and its 
pathophysiology involves complex psychoneuroendocrinological parameters. The 
results of the present study showed that altered stress-related endocrinological 
interactions in post-menopausal BMS patients might affect the expression of oral 
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MUC1 and occurrence of oral burning sensations.
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Table 1. Characteristics of patients with BMS, mean ± S.D., or n (%).
Total participants (n) 30
Age (years) 60.0 ± 5.0
Symptom duration (months) 28.1 ± 39.3
Range 2 - 180
Salivary flow rate (mL/min)
UWS 0.27 ± 0.17







Taste disturbance 18 (60.0)
Dry mouth 20 (66.7)
Sore throat 15 (50.0)
Severity of symptoms (VAS)
Burning 6.1 ± 2.9
Aching 3.2 ± 3.7
Itching 0.8 ± 2.1
Stinging 2.3 ± 3.2
Numbness 0.9 ± 1.8
Taste disturbance 2.7 ± 3.1
Dry mouth 3.3 ± 2.8
Sore throat 2.6 ± 3.2





Buccal mucosa 2 (6.7)
Gingival/alveolar mucosa 5 (16.7)
Mouth floor 1 (3.3)
Teeth 2 (6.7)
Parafunctional habits
Pressing the tongue against teeth 8 (26.7)
Diurnal clenching 6 (20.0)
Nocturnal clenching and/or bruxism 3 (10.0)
Tongue and/or cheek biting 3 (10.0)
BMS, burning mouth syndrome; VAS, visual analog scale; Eff-life, the effect 
of oral complaints on daily life
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Table 2. Salivary levels of cortisol, DHEA, cortisol/DHEA, 17ß-estradiol, 
progesterone, CgA, and blood contamination in patients with BMS.
n = 30 Mean ± S.D.
Cortisol (μg/dL)
UWS 0.28 ± 0.25
SWS 0.24 ± 0.16
DHEA (pg/mL) 
UWS† 65.3 ± 45.0
SWS 54.3 ± 35.9
Cortisol/DHEA
UWS† 79.4 ± 87.2
SWS 73.6 ± 74.0
17ß-Estradiol (pg/mL)
UWS 1.01 ± 0.56
SWS 1.21 ± 0.45
Progesterone (pg/mL)
UWS 40.2 ± 41.6
SWS 24.5 ± 18.4
CgA (pmol/mL)
UWS† 62.3 ± 37.1
SWS 40.0 ± 18.0
Blood (mg/dL)
UWS 0.83 ± 0.45
SWS 0.36 ± 0.20
BMS, burning mouth syndrome; UWS, unstimulated whole saliva; SWS, 
stimulated whole saliva; DHEA, dehydroepiandrosterone; CgA, chromogranin 
A; Blood, blood contamination
† In one UWS sample, assays of DHEA and CgA could not be performed due 
to a shortage of sample (n = 29).
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Table 3. Correlation coefficients between the results of salivary analyses and 
clinical symptoms.
n = 30 Symptom duration Burning (VAS) Eff-life (VAS)
MUC1 -.215 .055 .093
Flow rate
  UWS .141 .177 .120
  SWS -.033 .209 -.019
Cortisol 
  UWS -.204 -.391* -.357
  SWS -.239 -.202 -.294
DHEA
  UWS† -.056 .316 .068
  SWS -.210 .226 -.010
Cortisol/DHEA
  UWS† -.140 -.517** -.246
  SWS .103 -.401* -.139
17β-Estradiol
  UWS .626** .184 .165
  SWS .250 .277 .397*
Progesterone 
  UWS -.166 .161 -.016
  SWS -.167 .065 .072
CgA
  UWS† .094 -.265 -.185
  SWS .020 -.327 -.273
Blood 
  UWS -.261 -.405* -.149
  SWS -.014 -.222 .229
VAS, visual analog scale; UWS, unstimulated whole saliva; SWS, stimulated 
whole saliva; DHEA, dehydroepiandrosterone; CgA, chromogranin A; Blood, 
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blood contamination; Eff-life, the effect of oral complaints on daily life
† In one UWS sample, assays of DHEA and CgA could not be performed due to a 
shortage of sample (n = 29).
*P < 0.05, **P < 0.01 by Pearson’s correlation analysis
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Table 4. Correlations between levels of oral mucosal MUC1 expression, salivary 












MUC1 .002 .186 .037 .009 .065 .550** .305 .304
Flow 
rate
-.041 .242 -.225 .045 .074 -.203 -.199
Cortisol .332 .182 .026 .428* .125 .248
DHEA† -.633** .346 .510** .071 .045
Cortisol
/DHEA†









UWS, unstimulated whole saliva; DHEA, dehydroepiandrosterone; CgA, 
chromogranin A; Blood, blood contamination
† In one UWS sample, assays of DHEA and CgA could not be performed due to a 
shortage of sample (n = 29).
*P < 0.05, **P < 0.01 by Pearson’s correlation analysis
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Table 5. Correlations between levels of oral mucosal MUC1 expression, salivary 












MUC1 -.052 .106 -.127 0.214 -.117 .414* .142 .038
Flow 
rate
.258 .173 -.173 -.245 .181 -.439* -.352
Cortisol .477** -.022 -.074 .409* .008 .114
DHEA -.626** .363* .538** -.024 .231
Cortisol
/DHEA








SWS, stimulated whole saliva; DHEA, dehydroepiandrosterone; CgA, 
chromogranin A; Blood, blood contamination
*P < 0.05, **P < 0.01 by Pearson’s correlation analysis
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Supplementary Table S1. Correlation coefficients between symptom duration, severities of symptoms and Eff-life, and results from 
psychological evaluation.
SOM, somatization; O-C, obsessive-compulsive; I-S, interpersonal sensitivity; DEP, depression; ANX, anxiety; HOS, hostility; PHOB, 
phobic anxiety; PAR, paranoid ideation; PSY, psychoticism; GSI, global severity index; PSDI, positive symptom distress index; PST, positive 
symptom total; Eff-life, the effect of oral complaints on daily life
*P < 0.05, **P < 0.01 by Pearson’s correlation analysis
SOM O-C I-S DEP ANX HOS PHOB PAR PSY GSI PSDI PST
Symptom 
duration
.052 .363* .139 .214 -.028 .312 -.052 .214 .031 .155 .248 .101
B rning .221 .231 .120 .202 .096 .317 .076 .185 .269 .264 .252 .227
Aching .162 .167 .150 .207 .205 .380* .343 .104 .286 .254 .219 .182
Itching .121 .071 -.066 .083 -.072 .190 .014 .010 .014 .100 .166 .091
Stinging .199 .207 .342 .325 .322 .360 .275 .326 .198 .348 .108 .337
Numbness .195 .336 .280 .169 .250 .272 .751** .304 .308 .361* .124 .443*
Taste disturbance .305 .216 .265 .492** .418* .238 .407* .152 .383* .412* .297 .308
Dry mouth .348 .266 .080 .057 .125 .143 .304 .198 .149 .275 .160 .307
Sore throat .265 -.069 -.241 -.170 -.157 .003 .176 -.197 .010 .025 .237 -.049
Eff-life .152 .223 .084 .219 .091 .377* .350 .121 .288 .261 .323 .173
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Supplementary Table S2. Correlation coefficients between level of oral mucosal MUC1 expression, salivary flow rates, levels of female 
gonadal hormones and stress markers, and results from psychological evaluation. 
SOM O-C I-S DEP ANX HOS PHOB PAR PSY GSI PSDI PST
MUC1 -.088 -.219 -.217 -.361 -.348 -.183 -.336 -.144 -.296 -.267 -.139 -.290
Flow rate
  UWS -.167 -.245 -.186 -.283 -.234 .071 -.135 .138 -.152 -.201 -.235 -.111
  SWS -.077 -.164 -.086 -.227 .030 .024 -.018 .037 -.088 -.084 -.214 .001
Cortisol 
  UWS -.085 -.301 -.033 -.284 -.076 -.234 -.182 -.129 -.234 -.230 -.123 -.275
  SWS -.152 -.229 -.095 -.196 .009 -.228 -.216 -.125 -.253 -.201 -.051 -.225
DHEA
  UWS† -.056 -.131 -.182 -.011 .203 -.158 -.191 -.216 -.016 -.062 .064 -.145
  SWS .057 -.113 -.032 .151 .329 -.125 -.148 -.161 .187 .056 .014 .054
Cortisol/DHEA
  UWS† -.084 -.090 .018 -.079 -.249 .027 .012 -.143 -.209 -.128 -.164 -.105
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UWS, unstimulated whole saliva; SWS, stimulated whole saliva; DHEA, dehydroepiandrosterone; CgA, chromogranin A; Blood, blood
contamination; SOM, somatization; O-C, obsessive-compulsive; I-S interpersonal sensitivity; DEP, depression; ANX, anxiety; HOS, hostility; 
PHOB, phobic anxiety; PAR, paranoid ideation; PSY, psychoticism; GSI, global severity index; PSDI, positive symptom distress index; PST, 
positive symptom total
  SWS -.208 .019 -.157 -.208 -.350 .015 -.121 -.176 -.378* -.242 -.096 -.274
17β-Estradiol
  UWS .054 .412* .116 .186 .077 .160 -.182 .027 -.007 .124 .195 .032
  SWS .278 .503** .251 .420* .341 .304 .134 .166 .461* .397* .270 .399*
Progesterone
  UWS .178 .053 -.023 -.149 -.032 -.074 -.230 -.019 -.100 .020 .027 -.005
  SWS .170 .026 .009 -.079 .087 -.052 -.163 -.066 -.016 .029 -.064 .043
CgA
  UWS† -.010 -.240 -.298 -.118 .122 -.217 -.192 -.238 -.108 -.145 .016 -.206
  SWS -.230 -.194 -.386* -.106 -.083 -.475** -.357 -.367* -.181 -.268 .104 -.337
Blood
  UWS -.133 -.433* -.310 -.107 .009 -.308 -.130 -.350 -.287 -.223 -.154 -.260
  SWS -.052 -.193 -.035 .193 .212 -.082 .107 -.095 .087 .030 .120 .000
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† In one UWS sample, assays of DHEA and CgA could not be performed due to a shortage of sample (n = 29).
*P < 0.05, **P < 0.01 by Pearson’s correlation analysis
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국문 초록
Relationships between Oral MUC1 Expression 
and Salivary Hormones in Burning Mouth 
Syndrome
구강작열감증후군 환자의 구강점막 상피세포 MUC1의





(지도교수: 고 홍 섭)
구강작열감증후군은 복잡하고 다양한 병인으로 인하여 발생하는
질환으로 신경계-정신계-내분비계 조절 기전 이상 및 구강점막의 완전성
저하가 주요한 병인 중 하나로 생각되고 있다. 이번 연구는 구강작열감
증후군 환자에서 구강상피 MUC1의 발현량과 타액 내 여성 호르몬과 스
트레스 표지자의 농도 및 임상적 증상과의 상관관계를 비교하고자 시행
되었다. 
본 연구에서는 폐경 이후의 여성 구강작열감증후군 환자 30명
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(평균 60.0 ± 5.0세)을 대상으로 임상검사 및 Symptom Checklist-90-
Revised를 활용한 심리학적 평가를 시행하였으며 구강점막 상피세포
MUC1의 상대적 발현량을 측정하였다. 그리고 비자극성 타액과 자극성
타액 검체를 이용하여 cortisol, dehydroepiandrosterone, 17β-estradiol, 
progesterone, chromogranin A의 농도와 혈액오염 정도를 측정하였다.
연구 결과, 타액 내 progesterone의 농도는 구강점막 상피세포
MUC1의 발현 정도, 타액 내 cortisol 농도 및 DHEA 농도와 유의미한
양의 상관관계를 보였다. 타액 내 17β-estradiol 농도는 구강 증상의 기
간, 구강 증상으로 인한 일상 생활의 지장 정도 및 심리학적 평가 결과
와 유의미한 양의 상관관계를 보였다. 비자극성 타액 내의 cortisol 농도
와 비자극성 및 자극성 타액 내에서의 cortisol/DHEA 비율은 구강작열감
의 심각도와 유의미한 음의 상관관계를 나타내었다. 이와 함께 미각이상
으로 인한 불편감의 정도는 심리학적 평가 결과와 유의미한 양의 상관관
계를 보였다. 
결론적으로 심리내분비학적 상호조절 기전 이상은 폐경기 구강
작열감증후군 환자의 구강점막 상피세포 MUC1의 발현 및 구강작열감의
정도에 영향을 미침을 알 수 있었다.
__________________________________________________________________
주요어: MUC1, 스트레스, 성호르몬, 타액, 구강작열감증후군
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